the product in the database has an inactive status
indications:
Malignant testicular tumors in combination with other cytostatics, small-cell lung carcinoma - in combination chemotherapy as first-line treatment.
Composition:
1 ampoule (5 ml) contains 100 mg etoposide.
Action:
Semi-synthetic derivative of podophyllotoxins with cytostatic activity. It causes the inhibition of metaphase acting mainly in the G2 phase of the cell cycle. The effect of the drug is inhibition of cell division in the phase of prophase (low doses) or lysis of cells entering the phase of mitosis (high doses). No changes are observed in microtubules. The main effect of the drug is the inhibition of DNA synthesis. Etoposide penetrates well into tissues, mainly kidneys, intestines, liver, thyroid, adrenal glands. It binds 94% with plasma proteins. The elimination of the drug is two-phase: T0,5 the final elimination is 1.5 h and 4-12 h, respectively. Etoposide is excreted in 42-67% in urine; from this 2/3 in the unaltered state, up to 16% of the dose is excreted in the faeces. Etoposide hardly penetrates into the cerebrospinal fluid.
Contraindications:
Hypersensitivity to the drug, severe hepatic insufficiency, thrombocytopenia less than 50 G / l and granulocytopenia below 0.5 G / l. Pregnancy and breastfeeding. The safety and efficacy of the drug in children remain unexplored.
Precautions:
Pregnancy and lactation:
Side effects:
Bone marrow damage (leukopenia - nadir 7-14 day, thrombocytopenia - nadir 9-16 day, renewal after 3 weeks), nausea, vomiting, diarrhea, anorexia, stomatitis. Alopecia. Hypotension after a quick administration i.v. Less often: allergic reactions usually in the form of anaphylactoid reactions (chills, fever, tachycardia, shortness of breath, bronchospasm), but also acute anaphylactic reaction after the first dose. Rash, urticaria, pruritus. Peripheral neuropathy. Irritation and inflammation of soft tissues following extravasation of the drug. Occasional: drowsiness, fatigue, liver damage, fever, abdominal pain, constipation, temporary cortical blindness. Hepatic impairment and metabolic acidosis after overdose.
Dosage:
Intravenously only in a drip infusion over 30-60 min .: 50- 100-mg / m2 body surface daily for 5 consecutive days or 100 mg / m2 pc. on days 1, 3 and 5 (usually in combination with other cytostatics). Treatment is repeated every 3-4 weeks. The dose should be modified to the extent of bone marrow function.
(C)
